MARKET OVERVIEW
Hospital acquired infections, or healthcare-associated infections (HAI) are nosocomially acquired infections that are typically absent or might be incubated at admission. Hospital acquired infections are usually acquired after hospitalization and apparent 48 hours after admission to the hospital. The infections are supervised intently by agencies for instance the National Healthcare Safety Network (NHSN) of the Center for Disease Control and Prevention (CDC). The supervision of hospital acquired infections is done in order to prevent HAI and improve patient safety in healthcare institutions and organization. HAI infections comprise hospital-acquired pneumonia (HAP), central line-associated bloodstream infections (CLABSI), ventilator-associated pneumonia (VAP), surgical site infections (SSI), catheter-associated urinary tract infections (CAUTI), and clostridium difficile infections (CDI). In the last few years, hospitals have taken the hospital acquired infections seriously as the riinsg prevalence of such infections are being the major cause of mortality. Several hospitals have established infection tracking and surveillance systems and robust prevention strategies to reduce the rate of hospital-acquired infections. The impact of hospital acquired infections is seen not just at an specific one patient level but also at the group level, as they have been linked to multidrug-resistant infections. Identifying patients with risk factors for hospital-acquired and multidrug-resistant infections is crucial in preventing and minimizing these infections. Furthermore, there are various types of treatment options for hospital acquired infections, that depends on the severity of the infection and the causative agent.
MARKET SCOPE
The "Global Hospital acquired infection treatment market analysis to 2030" is a specialized and in-depth study of the pharmaceutical industry with a special focus on global market trend analysis. The report aims to provide an overview of the hospital acquired infection treatment market with detailed market segmentation by drug class, infection type, and geography. The report provides key statistics on the market status of the leading hospital acquired infection treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The hospital acquired infection treatment market is segmented based on drug class, infection type, and region. Based on drug type, the global hospital acquired infection treatment market is differentiated into antibacterial drugs, antiviral drugs, and antifungal drugs. By infection type, the hospital acquired infection treatment market is classified into urinary tract infections, ventilator-associated pneumonia, surgical site infections, bloodstream infections and other hospital infections.
MARKET DYNAMICS
Drivers-
In the coming years, it is anticipated that the high prevalence of HAIs is expected to increase the demand for effective treatment to ensure complete and speedy recovery which in turn driving the market growth. According to the Organisation for Economic Co-operation and Development (OECD), every year, about 3.8 million people in EU nations contract an infection related to healthcare in acute care hospitals. The same source also claims that every year, approximately 90,000 people in EU nations died due to HAIs. The high incidence of HAI and rising antibiotic resistance have considerably increased the demand for new HAI therapies. As a result, prominent market players engage in extensive R&D efforts to create new HAI medications and secure their acceptance in important markets. In May 2023, Indian Institute of Science Education and Research (IISER) in Pune, and Council of Scientific & Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow has jointly discovered a antibiotic to cure hospital acquired infections.
Furthrmore, rising incidence of chronic conditions like cancer, heart disease, diabetes, and arthritis have increased the health concerns at global level. The American Cancer Society reported data showing that there were around 1.9 million new cancer cases worldwide in 2022. The number of hospital admissions has increased as a result of the increasing incidence of these chronic diseases which has further increased the incidence and prevalence of HAIs among these patients. For instance, the New York State Department of Health reported in November 2019 that around 40% of adults in the state have a chronic illness, which accounts for approximately 23% of all hospitalisations.
REGIONAL FRAMEWORK
North America accounts for largest revenue share in global hospital acquired infection treatment market in 2022. The high cost of hospital acquired infection treatment, as well as the increased awareness and affordability of the population in the region is expected to anticipate the market growth. Europe is expected to be the second largest market in hospital acquired infection treatment market and expected to closely follow the North America in coming years. The high frequency of hospital acquired infection treatment in European nations and the rising approval and introduction of innovative hospital acquired infection treatment medications in the region is expected to amplify the market growth. Moreover, region has the preesnce of various local market players operation in the market such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Allergan Plc, and Bayer AG providingaccessibility of novel hospital-acquired infection treatments in European nations.
Asia Pacific is expected to show significant growth owing the presence of developing economies such as India, China and others that has increased prevelance of HAIs are driving the market growth in the region. Additionally, hospitalisation rates have increased due to the rising frequency of chronic diseases in developing nations like China and India. For instance, according to data from Springer Nature, there were approximately 2.7 million new cancer cases diagnosed in China in 2022. Therefore, increasing hopsitalizations due to chronic disease has further amplified the prevelance of HAIs which in turn contributing to the hospital acquired infection treatment market growth.
MARKET PLAYERS
The report covers key hospital acquired infection treatment market developments, such as organic and inorganic growth strategies. Various companies such as Merck and Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Allergan Plc., AstraZeneca and among others are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Inorganic growth strategies activities witnessed in the hospital acquired infection treatment market were acquisitions, partnerships & collaborations. These activities have paved the way for the expansion of business and the customer base of hospital acquired infection treatment market players. The market players from the hospital acquired infection treatment market are anticipated to have lucrative growth opportunities with the rising demand for hospital acquired infection treatment in the global market.
Key Developments in Global Hospital acquired infection treatment market
- In May 2023, Innoviva Specialty Therapeutics received FDA approval for Xacduro, it's a new antibiotics which used to treat hospital acquired infection.
- In May 2023, Indian Institute of Science Education and Research (IISER) in Pune, and Council of Scientific & Industrial Research-Central Drug Research Institute (CSIR-CDRI), Lucknow has jointly discovered a antibiotic to cure hospital acquired antibiotic.
- In June 2020, Merck get FDA approval for Recarbrio. It advances the treatment for hospital-acquired infections, such as ventilator-associated bacterial pneumonia, caused by difficult to treat Gram-negative organisms.
- In June 2019, FDA has approved new treatment for hospital-acquired and ventilator-associated bacterial pneumonia.
The hospital acquired infection treatment market report also includes key companies' profiles, their SWOT analysis, and hospital acquired infection treatment market size and strategies. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information for the last three years, and key development in the past five years.
The Insight Partner's dedicated research and analysis team comprises experienced professionals with advanced statistical expertise and offers various customization options in the current study.